The production facility in Herøya has now begun commercial operations. Pb-212, Th-228, and Ra-224 are produced there; the first shipments to customers are already expected in August 2026. Capacity is to be gradually increased to 21,000 patient doses over the next three years.
CEO Jasper Kurth explains that the company now holds a leading position in the commercial supply of critical isotopes to the radiopharmaceutical industry.
I still believe it’s possible to get in on this. The fact that AlphaOne is already in production and deliveries are set to begin next month is a major step. However, the real potential could lie with AlphaTwo, which is expected to have a capacity about ten times greater.
Trmed - Thor Medical
[https://www.thormedical.com/artikler/thor-medical-asa-alphaone-starts-commercial-production](https://www.thormedical.com/artikler/thor-medical-asa-alphaone-starts-commercial-production)